1,051 followers
Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report https://t.co/X6wCqgYlrh
Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report https://t.co/X6wCqgYlrh
RT @FrontOncology: New research: Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report: Alpelisib plus fulvestrant is a…
New research: Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report: Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative… https://t.co/cKF